No Data
Youcare Pharmaceutical Group to Terminate Coding System Project
Youcare Pharmaceutical Group (688658.SH): plans to use the remaining raised surplus funds of 38.4278 million yuan to permanently supplement working capital.
On December 18, Gelonghui reported that Youcare Pharmaceutical Group (688658.SH) announced that it will hold the 17th meeting of the second Board of Directors and the 15th meeting of the second Supervisory Board on December 18, 2024. The meetings reviewed and approved the proposal on the permanent supplement of working capital using the remaining excess fundraising. The company agreed to use the remaining excess fundraising of 38.4278 million yuan (including interest and cash management income, with the specific amount based on the actual amount at the time of transfer) to permanently supplement working capital, which accounts for 7.50% of the total excess fundraising.
Youcare Pharmaceutical Group (688658.SH): Termination of some fundraising investment projects.
On December 18th, Gelonghui reported that Youcare Pharmaceutical Group (688658.SH) announced that the fundraising investment project "Intelligent Coding System Construction Project" was developed by the company in consideration of factors such as the current market environment, Industry development trends, and the company's actual situation. Although the company conducted sufficient research and demonstrations at the project's initiation, in recent years, there have been significant changes in the pharmaceutical Industry and the generic drug market. Additionally, influenced by several uncontrollable factors such as the company's external severe situation and local policy changes, the company plans to decide, in light of actual Business needs, to improve the efficiency of the raised funds and ensure their effective use.
Youcare Pharmaceutical's Cefprozil Tablets Pass Regulator's Consistency Evaluation
Youcare Pharmaceutical's Unit Gets Nod to Trial Herpes Drug in US
youcare pharmaceutical group (688658.SH): Subsidiary YKYY026 injection solution obtained FDA clinical trial approval
On December 5th, Glonghui reported that youcare pharmaceutical group (688658.SH) announced that its wholly-owned subsidiary, Hangzhou Tianlong Pharmaceutical Co., Ltd., recently received a notification from the usa Food and Drug Administration (referred to as "FDA") regarding the approval for clinical trials of YKYY026 injection for the prevention of shingles. YKYY026 injection is an mRNA vaccine independently developed by Hangzhou Tianlong, encoding the varicella-zoster virus (VZV) gE protein antigen, used to prevent shingles.
Some Confidence Is Lacking In Youcare Pharmaceutical Group Co., Ltd. (SHSE:688658) As Shares Slide 26%
